Home › Companies › APVO

Aptevo Therapeutics

Market cap $1.6M 3.5M shares (10-Q, Nov 16, 2026) × $0.461 close Nov 17, 2026

Most recent annual filing: 2026-03-26

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. Mipletamig Ph2 readoutyear-end 2026Mipletamig Ph2 readout, year-end 2026, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Technology platforms

ADAPTIR

ADAPTIR protein technology platform for rational design of monospecific and bispecific immunotherapeutic proteins targeting cancer; generates molecules that bind one or more targets with structural and functional advantages over monoclonal antibodies; used to develop clinical and preclinical oncology candidates

Targets: CD3, Nectin-4, PD-L1, CD40

ADAPTIR-FLEX

Proprietary flexible multispecific immunotherapy platform enabling adjustable construct design and addition of different therapeutic components; supports development of bispecific and trispecific candidates for solid tumors and hematologic malignancies, including Nectin-4 x PD-L1 backbone applications.

Targets: CD3, Nectin-4, PD-L1, CD40

Capital (as filed)

Cash
$8.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$5.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$8.3M cash, runway Q1 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on Aptevo Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Avoid Aptevo Therapeutics (APVO) - Scientific Deep Dive for Mipletamig, ALG.APV-527, and the ADAPTIR Pipeline Serial-dilution microcap with an unproven CRS-sparing CD123xCD3 in a class larger players are abandoning, an evaluable-vs-ITT efficacy pitch that cannot demonstrate additive benefit without a control arm, a stalled partner-encumbered second program, and an explicit going-concern qualification.
  2. Avoid UPDATE: Aptevo Therapeutics (APVO) - The Warrant Treadmill Turns Again $4.5M gross against ~$8.0M/quarter burn is a bridge to the next bridge, with new warrant overhang capping any RAINIER catalyst pop while the efficacy claim remains structurally unprovable.
  3. Avoid UPDATE: Aptevo Therapeutics (APVO) - They Just Locked Their Own Piggy Bank Management traded away 12 months of access to $66.8M in equity-line capacity for $4.5M gross, leaving the company with ~$9.8M cash, a restated going-concern, and a warrant plan struck 27% above the current price.
  4. Avoid UPDATE: Aptevo Therapeutics (APVO) - Good Data, Wrong Week A 79% CR/CRi in 14 TP53-mutant patients is the strongest clinical signal yet but cannot outrun 6.4 million registered resale shares against a 1.81 million share float, with warrants 58% out of the money and the capital plan effectively non-functional.
  5. Avoid UPDATE: Aptevo Therapeutics (APVO) - Five Warrants for Every Share $3.0M gross raise issues 13.9M new warrants at $1.08 while the stock closes at $0.76, starting the Nasdaq delisting clock with no cure period available and the equity lines still locked.
  6. Avoid UPDATE: Aptevo Therapeutics (APVO) - The Equity Cliff Three simultaneous Nasdaq listing tests, equity lines frozen until November 2027, ~$11M pro forma cash against ~$6.5M/quarter burn, and stockholders' equity near the $2.5M floor — the structure is deteriorating faster than the clinical signal is advancing.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (45)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)